Who has been buying Billions stock?

2 distinct insiders have filed 0 disclosed insider purchases in Billions (044480), most recently on 2026-05-11. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Billions have?

Billions has 0 buy-side and 2 sell-side disclosures on record, covering ₩940M ($653K) in total reported value, spanning 2024-02-13 to 2026-05-11.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Billions 044480

Company

빌리언스Billions

Insiders

Buys

Total Value

₩940M ($653K)

Avg Return

+6.51%

Last Filing

2026-05-11

Billions (044480) has 0 disclosed insider purchases and 2 disclosed disposals on record, filed by 2 distinct insiders. Together those filings cover ₩940M ($653K) in reported transaction value. The earliest filing StockDrifts holds for Billions is dated 2024-02-13; the most recent is 2026-05-11. Across these filings the average return since disclosure is +6.51%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-08-19	SELL	주식병합	휴마시스 Humasis	-	-10.7M	₩820	+0.0%	₩8.7B ($6.1M)
2026-05-11	BUY	장외매수	디지털브리지 신기술 투자조합 Digital Bridge New Technology Investment Association	-	5.4M	-	-	-
2026-04-21	BUY	행사가액조정	휴마시스 Humasis	-	284.7K	₩445	+0.0%	₩127M ($88K)
2026-04-21	BUY	유상신주취득	휴마시스 Humasis	-	7.8M	₩445	+0.0%	₩3.5B ($2.4M)
2026-04-21	SELL	Market Sell	휴마시스 Humasis	-	-1.9M	₩445	+0.0%	₩829M ($576K)
2026-04-17	BUY	행사가액조정	휴마시스 Humasis	-	121.0K	₩445	+0.0%	₩54M ($37K)
2026-04-16	SELL	주식병합	휴마시스 Humasis	-	-21.9M	₩445	+0.0%	₩9.7B ($6.8M)
2026-04-16	SELL	행사가액조정	휴마시스 Humasis	-	-5.8M	₩445	+0.0%	₩2.6B ($1.8M)
2026-04-01	SELL	행사가액조정	휴마시스 Humasis	-	-1.9M	₩326	-36.5%	₩614M ($427K)
2026-03-31	SELL	임원퇴임	심화석 Shim Seok Sim	CEO	-786.1K	₩312	-42.6%	₩245M ($170K)
2026-03-03	BUY	행사가액조정	휴마시스 Humasis	-	470.3K	₩221	+45.3%	₩104M ($72K)
2026-03-03	BUY	행사가액조정	경남제약 Kyungnam Pharmaceutical	-	1.2M	₩221	+45.3%	₩263M ($182K)
2026-02-02	BUY	행사가액조정	휴마시스 Humasis	-	887.1K	₩269	+19.3%	₩239M ($166K)
2026-02-02	BUY	행사가액조정	경남제약 Kyungnam Pharmaceutical	-	2.2M	₩269	+19.3%	₩603M ($419K)
2026-01-02	BUY	행사가액조정	경남제약 Kyungnam Pharmaceutical	-	1.4M	₩301	+6.6%	₩435M ($302K)
2026-01-02	BUY	행사가액조정	휴마시스 Humasis	-	571.6K	₩301	+6.6%	₩172M ($119K)
2025-12-01	BUY	행사가액조정	경남제약 Kyungnam Pharmaceutical	-	2.5M	₩323	-0.6%	₩822M ($571K)
2025-12-01	BUY	행사가액조정	휴마시스 Humasis	-	1.0M	₩323	-0.6%	₩325M ($226K)
2025-11-03	BUY	행사가액조정	휴마시스 Humasis	-	944.1K	₩350	-8.3%	₩330M ($229K)
2025-11-03	BUY	행사가액조정	경남제약 Kyungnam Pharmaceutical	-	2.4M	₩350	-8.3%	₩835M ($580K)
2025-10-01	SELL	행사가액조정	경남제약 Kyungnam Pharmaceutical	-	-9.5M	₩397	+19.1%	₩3.8B ($2.6M)
2025-10-01	SELL	행사가액조정	휴마시스 Humasis	-	-3.8M	₩397	+19.1%	₩1.5B ($1.0M)
2025-09-13	BUY	행사가액조정	휴마시스 Humasis	-	3.4M	₩505	-36.4%	₩1.7B ($1.2M)
2025-09-13	SELL	기타	휴마시스 Humasis	-	-13.6M	₩505	+36.4%	₩6.9B ($4.8M)
2025-09-13	BUY	행사가액조정	경남제약 Kyungnam Pharmaceutical	-	10.5M	₩505	-36.4%	₩5.3B ($3.7M)
2025-09-13	BUY	유상신주취득	휴마시스 Humasis	-	13.6M	₩505	-36.4%	₩6.9B ($4.8M)
2025-09-10	BUY	행사가액조정	경남제약 Kyungnam Pharmaceutical	-	99.7K	₩408	-21.3%	₩41M ($28K)
2025-09-05	SELL	기타	심화석 Shim Seok Sim	CEO	-473.3K	₩432	+25.7%	₩204M ($142K)
2025-09-01	SELL	행사가액조정	경남제약 Kyungnam Pharmaceutical	-	-4.9M	₩468	+31.4%	₩2.3B ($1.6M)
2025-09-01	SELL	행사가액조정	휴마시스 Humasis	-	-1.9M	₩468	+31.4%	₩905M ($628K)
2025-08-28	SELL	Market Sell	심화석 Shim Seok Sim	CEO	-300.0K	₩369	+13.0%	₩111M ($77K)
2025-08-19	BUY	기타	심화석 Shim Seok Sim	CEO	773.3K	₩415	-22.6%	₩321M ($223K)
2025-08-11	BUY	행사가액조정	경남제약 Kyungnam Pharmaceutical	-	203.0K	₩570	-43.7%	₩116M ($80K)
2025-08-08	BUY	기타	휴마시스 Humasis	-	13.6M	₩439	-26.9%	₩6.0B ($4.1M)
2025-08-01	BUY	행사가액조정	휴마시스 Humasis	-	2.8M	₩303	+5.9%	₩860M ($597K)
2025-04-01	BUY	행사가액조정	경남제약 Kyungnam Pharmaceutical	-	1.3M	₩416	-22.8%	₩551M ($382K)
2025-04-01	BUY	행사가액조정	휴마시스 Humasis	-	524.0K	₩416	-22.8%	₩218M ($151K)
2025-03-04	SELL	행사가액조정	경남제약 Kyungnam Pharmaceutical	-	-1.3M	₩447	+28.2%	₩592M ($411K)
2025-03-04	SELL	행사가액조정	휴마시스 Humasis	-	-524.0K	₩447	+28.2%	₩234M ($163K)
2025-01-02	BUY	행사가액조정	경남제약 Kyungnam Pharmaceutical	-	1.4M	₩463	-30.7%	₩657M ($456K)
2025-01-02	BUY	행사가액조정	휴마시스 Humasis	-	561.3K	₩463	-30.7%	₩260M ($180K)
2024-12-10	BUY	행사가액조정	경남제약 Kyungnam Pharmaceutical	-	573.5K	₩460	-30.2%	₩264M ($183K)
2024-12-02	BUY	행사가액조정	휴마시스 Humasis	-	217.1K	₩480	-33.1%	₩104M ($72K)
2024-12-02	BUY	행사가액조정	경남제약 Kyungnam Pharmaceutical	-	548.6K	₩480	-33.1%	₩263M ($183K)
2024-11-10	BUY	행사가액조정	경남제약 Kyungnam Pharmaceutical	-	64.4K	₩573	-44.0%	₩37M ($26K)
2024-11-01	BUY	행사가액조정	경남제약 Kyungnam Pharmaceutical	-	1.0M	₩547	-41.3%	₩560M ($389K)
2024-11-01	BUY	행사가액조정	휴마시스 Humasis	-	405.5K	₩547	-41.3%	₩222M ($154K)
2024-10-10	BUY	행사가액조정	경남제약 Kyungnam Pharmaceutical	-	133.9K	₩654	-50.9%	₩88M ($61K)
2024-10-02	BUY	행사가액조정	휴마시스 Humasis	-	352.3K	₩645	-50.2%	₩227M ($158K)
2024-10-02	BUY	행사가액조정	경남제약 Kyungnam Pharmaceutical	-	889.9K	₩645	-50.2%	₩574M ($399K)

Showing the 50 most recent of 81 filings.

Frequently asked questions

Who has been buying Billions stock?: 2 distinct insiders have filed 0 disclosed insider purchases in Billions (044480), most recently on 2026-05-11. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Billions have?: Billions has 0 buy-side and 2 sell-side disclosures on record, covering ₩940M ($653K) in total reported value, spanning 2024-02-13 to 2026-05-11.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.